A retrospective study of 500 mg fulvestrant in recurrent or metastatic breast cancer patients pretreat-ed with the third generation of aromatase inhibitors
10.19401/j.cnki.1007-3639.2016.09.009
- VernacularTitle:500 mg氟维司群治疗既往接受芳香化酶抑制剂治疗的复发转移性乳腺癌患者的回顾性研究
- Author:
Yannan ZHAO
;
Chengcheng GONG
;
Xichun HU
;
Zhonghua WANG
;
Jian ZHANG
;
Leiping WANG
;
Jun CAO
;
Zhonghua TAO
;
Biyun WANG
- Publication Type:Journal Article
- Keywords:
Fulvestrant;
Metastatic breast cancer;
Estrogen receptor positive;
Aromatase inhibitor
- From:
China Oncology
2016;26(9):777-783
- CountryChina
- Language:Chinese
-
Abstract:
Background and purpose:The third generation of aromatase inhibitors (AI) in postmenopausal hormone receptor-positive patients is the routine treatments in endocrine therapy. The 500 mg fulvestrant showed clini-cal beneifts in patients with previous AI treatment. This study aimed to access the effcacy and safety of 500 mg fulves-trant in estrogen receptor (ER) positive postmenopausal patients who had previous AI treatments with locally advanced and metastatic breast cancer.Methods:This study retrospectively analyzed the clinical data from 188 post-AI ER positive and (or) progesterone receptor (PR)-positive locally advanced and metastatic breast cancer patients treated with 500 mg fulvestrant in Fudan University Shanghai Cancer Center from Jul. 2011 to Dec. 2015. Primary end point was progression-free survival (PFS). Secondary end points were objective response rate (ORR), clinical beneift rate (CBR) and safety proifle.Results:After the median follow-up of 11.3 months, median PFS was 5.9 months (95%CI: 4.2-7.5), CBR was 40.0% and ORR was 3.4%. COX proportional hazards regression analysis indicated that PFS was correlated with the number of metastatic sites (HR=1.92, 95% CI: 1.2-2.9,P =0.002) and previous lines of chemotherapy (HR=1.52, 95%CI:1.0-2.1,P=0.022). Six patients stopped the treatment for intolerable adverse events.Conclusion:The treatment of 500 mg fulvestrant has a favorable effcacy and safety in treatment of post-AI ER positive postmenopausal patientswith metastatic breast cancer.
